Beta Bionics (BBNX) investor relations material

Business performance and market trends

• Achieved a strong Q1 with revenue exceeding expectations by 2.5%, driven by increased adoption in the pharmacy channel, where patient out-of-pocket costs are significantly lower than DME reimbursement.

• Expanded the field sales team in Q1 2026 and plan to add at least 20 new U.S. territories in the first half of 2026 to boost product adoption and awareness.

• Maintains a differentiated product with strong confidence in clinical outcomes and automation, outperforming competitors in the tubed insulin pump market.

• Sees the pump market as healthy, with continued growth in both Type 1 and Type 2 diabetes segments, and expects sustained double-digit growth.

• New patient starts are considered predictable due to historical data and territory ramp rates, with ongoing market share gains in the tubed pump segment.

Product innovation and competitive positioning

• Plans to launch a patch pump, Mint, by the end of 2027, with manufacturing readiness as the primary gating factor.

• Mint's design features a reusable portion lasting two years and a disposable portion replaced every three days, with no recharging required, simplifying manufacturing compared to competitors.

• Manufacturing expertise is established, with millions of disposable products already produced in clean room environments.

• Differentiation will increasingly depend on algorithm performance, clinical outcomes, and ease of use for both patients and providers.

• Ongoing innovation in algorithms, including fully closed-loop and bi-hormonal technology, is a strategic focus.

Pharmacy channel strategy and reimbursement

• Pharmacy channel adoption is a major advantage, offering lower patient out-of-pocket costs and a recurring revenue model, which is preferred by payers.

• Insulin pumps are not commoditized, and pricing in the pharmacy channel is expected to remain rational and sustainable due to product differentiation and patient-specific prescribing.

• Tier 2 and Tier 3 pharmacy benefit positions are chosen based on economic modeling of rebates and copay buy-downs, with patients experiencing no difference due to copay assistance.

• Payers prefer the pharmacy model for better risk transfer, increased pump adoption, and reduced administrative burden compared to DME.

• Transitioning existing DME patients to the pharmacy channel is straightforward, with no blocking mechanisms in place.